Altimmune's CEO recently purchased 15,000 shares at $2.95 each, showing strong leadership confidence in the company's future. The biopharmaceutical firm reported a better-than-expected Q2 loss of $0.12 per share and holds $519 million in cash, securing funding through 2029. Increased R&D spending supports the Phase III PERFORMA trial for its MASH treatment, pemvidutide, alongside positive Phase II results for alcohol use disorder. These developments highlight Altimmune's promising pipeline and financial stability as it advances toward regulatory approval.
Ripple has signed a multi-year sponsorship with University of Florida Athletics, starting the 2026 football season, featuring XRP branding at Ben Hill Griffin Stadium, known as "The Swamp." The deal, estimated at up to $5 million annually, includes f...
DASH surged 17.5% to $56.85, its highest since May, driven by a rally in privacy coins and Grayscale's spot Zcash ETF surpassing $400M in assets. The token gained about 85% from mid-August lows near $30, supported by bullish technical signals like a ...
Pineapple Financial, a mortgage lender listed on NYSE American, has tokenized over $1 billion in residential mortgage data on the Injective blockchain, marking a major step in blending traditional finance with blockchain technology. The project start...
Polymarket plans a $1 billion funding round valuing the prediction market platform at $21 billion, led by Donald Trump Jr.'s 1789 Capital. Cronos reversed its blockchain after a $75 million exploit in the Tectonic lending protocol, restoring the netw...
Investment-grade credit default swap (CDS) prices fell below 50 basis points, nearing lows not seen since February 2020, indicating improved credit market confidence. Meanwhile, the VIX volatility index dropped below 14 for the first time since Decem...
